临床诊断特征的进展和轻度认知障碍的认知衰退与勒维体
Calum Alexander Hamilton1, Paul C Donaghy1, John-Paul Taylor1
1Translational and Clinical Research Institute, https://ror.org/01kj2bm70Newcastle University, Newcastle upon Tyne, UK.
Psychological medicine
|June 24, 2025
概括
患有莱维体的轻度认知障碍 (MCI-LB) 在出现更多症状时进展更快. 在MCI-LB中,视觉幻觉和认知波动表明预后更差,认知衰退加速.
科学领域:
- 神经学 神经学
- 认知科学 认知科学
- 老年病的医生 老年病的医生
背景情况:
- 莱维体轻度认知障碍 (MCI-LB) 呈现认知衰退和核心特征,如视觉幻觉,认知波动,帕金森症和REM睡眠行为障碍.
- MCI-LB的临床表现可能会有所不同,可能反映出潜在的病理,疾病严重程度或并发症.
研究的目的:
- 评估MCI-LB中临床特征的纵向积累.
- 确定这些特征的积累是否与认知能力下降的速度相关.
主要方法:
- 一项前性队列研究,涉及74名患有MCI-LB的个人.
- 每年进行多达9年的认知和临床评估.
- 使用时间变化的混合模型和多状态马尔科夫模型来分析临床特征和认知变化 (ACE-R分数).
主要成果:
- 具有更多MCI-LB临床特征的个人经历了更快的认知衰退 (β = -1.1).
- 视觉幻觉 (β = -2.1) 和认知波动 (β = -3.4) 特别与加速衰退有关.
- 每年获得新特征的概率很高 (25.5%),仅仅降低了基线特征的预后价值.
结论:
- 随着时间的推移,MCI-LB的临床表现会发生变化.
- 勒维体病特征的累积,特别是视觉幻觉和认知波动,与MCI-LB患者的预后较差有关.
- 对临床特征的纵向评估对于了解MCI-LB进展和预后至关重要.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.0K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
相关概念视频
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722
Cognitive Development During Adulthood
303
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
303
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
